ADVANCING THE CARDIOVASCULAR CARE OF THE

ONCOLOGY PATIENT

Disclosure/Conflict of Interest Statement

As a provider jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), the American College of Cardiology Foundation (ACCF) must ensure balance, independence, objectivity, and scientific rigor in all of their directly provided or jointly provided/co-provided educational activities. Planners, presenters, and other contributors, in a position to control the content are required to disclose to the audience all relevant financial relationships he/she may have, occurring within the past 24 months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the contributor should disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCF is committed to providing its learners with high-quality activities and materials that promote improvements and quality in health care and not a specific proprietary business or commercial interest. The intent of this disclosure is not to prevent participation in educational activities by persons with a financial or other relationship, but rather to provide learners with information on which they can make their own determination whether financial interests or relationships may influence the education activity.

ACCF assesses conflicts of interest (COI) with its faculty, planners, managers, staff, and other individuals who are in a position to control the content of certified activities. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup (ACWG) through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations.

ACCF has taken the necessary steps to ensure that all relevant financial relationships have been mitigated.

Please note ACCF staff and the ACWG members involved with this activity have nothing to disclose.

ADVANCING THE CARDIOVASCULAR CARE OF THE

ONCOLOGY PATIENT



Ana Barac MD, PhD, FACC

Inova Health Systems

Disclosures

Data Safety Monitoring Board ACI Clinical

Bonnie Ky, MD, MSCE, FACC

University of Pennsylvania School of Medicine

Disclosures

Consultant Fees/Honoraria: AstraZeneca; Bristol

Meyers Squibb; Medscape; Pfizer Myovant

Research/Research Grants: Pfizer

Speaker's Bureau: Roche

Other - Research: Corvia; Impulse Dynamics;

Other - Author: Uptodate

Course Vice-Chair

Richard Cheng, MD, FACC

University of Washington

Disclosures

Nothing to disclose

Planning Committee

Alana Ferrari, PharmD, BCOP

University of Virginia Medical Center

Disclosures

Consultant Fees/Honoraria: Janssen

Pharmaceuticals, Inc

Teresa Lopez-Fernandez, MD

La Paz University Hospital

Disclosures

Consultant Fees/Honoraria: AstraZeneca; Bayer

Healthcare Pharmaceuticals; Philips Speaker's Bureau: Beigene; Daiichi Sankyo; Janssen Pharmaceuticals, Inc; Myocardial

Solutions; Pfizer Inc; Philips

Vivek Narayan, MD

Hospital of the University of Pennsylvania

Disclosures

Consultant Fees/Honoraria: Exelixis; Janssen Pharmaceuticals, Inc; Merck & Co., Inc.; Myovant;

Regeneron; Sanofi-Aventis

Research/Research Grants: Bristol Myers Squibb; Janssen Pharmaceuticals, Inc; Merck & Co., Inc.;

Pfizer Inc; Xencor

Alexi Vasbinder, PhD, RN

University of Michigan

Disclosures

Nothing to disclose.

Eric Yang, MD, FACC

University of California

Disclosures

Consultant Fees/Honoraria: Edwards Lifesciences;

Xencor

Research/Research Grants: Amgen; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb Company; CSL Behring; Eli Lilly and

Company

Faculty

Daniel Addison, MD

The Ohio State University

Disclosures

Nothing to disclose

Laleh Amiri-Kordestani, MD

U.S. Food and Drug Administration

<u>Disclosures</u>

Nothing to disclose

Cathleen Biga, MSN, FACC

Cardiovascular Management of Illinois

Disclosures

Nothing to disclose

Asma Dilawari, MD

U.S. Food and Drug Administration

Disclosures

Consultant Fees/Honoraria: Reimagine Care

Stephanie Dixon, MD

St. Jude Children's Research Hospital

Disclosures


Salary: Pacemate, LLC

Julia Maues

Disclosures

ADVANCING THE CARDIOVASCULAR CARE OF THE

ONCOLOGY PATIENT



Nicolas Palaskas, MD, FACC

MD Anderson Center

Disclosures

Consultant Fees/Honoraria: Kiniksa

Pharmaceuticals; National Comprehensive Cancer

Network; Physician Education Resource;

Replimmune; Scripps; Society for Immunotherapy

of Cancer

Danielle Shafer, DO

Inova Health System

Disclosures

Nothing to disclose

Lova Sun, MD

University of Pennsylvania

Disclosures

Consultant Fees/Honoraria: GenMab; Regeneron Research/Research Grants: Erasca; Immunocore; IO Biotech

Ronald Witteles, MD, FACC

Stanford University School of Medicine

Disclosures

Consultant Fees/Honoraria Alexion; Alnylam; AstraZeneca Pharmaceuticals; BridgeBio; Novo Nordisk Inc; Pfizer Inc

Partner Society Joint Sessions

Anne Blaes, MD, MS

ASCO Joint Session Planning Committee & University of Minnesota

Disclosures

Research/Research Grants: Dompe Pharmaceuticals.

Susan Dent, MD

ASCO Joint Session Faculty & Duke Cancer Center

<u>Disclosures</u>

Consultant Fees/Honoraria: AstraZeneca; Gilead Sciences, Inc.; Myocardial Solutions; Novartis; Pfizer Inc.